🇺🇸 FDA
Patent

US 11802283

Oligonucleotide analogues targeting human LMNA

granted A61PA61P43/00

Quick answer

US patent 11802283 (Oligonucleotide analogues targeting human LMNA) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61P, A61P43/00